Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Operating Leases (2023 - 2025)

Historic Operating Leases for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to $4.0 million.

  • Immunome's Operating Leases rose 6286.53% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year increase of 6286.53%. This contributed to the annual value of $4.8 million for FY2024, which is 25589.55% up from last year.
  • Immunome's Operating Leases amounted to $4.0 million in Q3 2025, which was up 6286.53% from $4.1 million recorded in Q2 2025.
  • In the past 5 years, Immunome's Operating Leases registered a high of $4.8 million during Q1 2025, and its lowest value of $1.2 million during Q1 2024.
  • For the 3-year period, Immunome's Operating Leases averaged around $2.9 million, with its median value being $2.5 million (2024).
  • As far as peak fluctuations go, Immunome's Operating Leases tumbled by 1000.0% in 2024, and later soared by 29552.24% in 2025.
  • Immunome's Operating Leases (Quarter) stood at $1.3 million in 2023, then surged by 255.9% to $4.8 million in 2024, then dropped by 15.85% to $4.0 million in 2025.
  • Its last three reported values are $4.0 million in Q3 2025, $4.1 million for Q2 2025, and $4.8 million during Q1 2025.